Cargando…
Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies?
During the last few decades, pediatric acute lymphoblastic leukemia (ALL) cure rates have improved significantly with rates exceeding 90%. Parallel to this remarkable improvement, there has been mounting interest in the long-term health of the survivors. Consequently, modified treatment protocols ha...
Autores principales: | Al-Mahayri, Zeina N., AlAhmad, Mohammad M., Ali, Bassam R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554193/ https://www.ncbi.nlm.nih.gov/pubmed/34722258 http://dx.doi.org/10.3389/fonc.2021.710163 |
Ejemplares similares
-
Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
por: Al-Mahayri, Zeina N., et al.
Publicado: (2020) -
Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Bernt, Kathrin M., et al.
Publicado: (2014) -
Pharmacogenomics at the post-pandemic: If not now, then when?
por: Al-Mahayri, Zeina N.
Publicado: (2022) -
The Profile of Immunophenotype and Genotype Aberrations in Subsets of Pediatric T-Cell Acute Lymphoblastic Leukemia
por: Noronha, Elda Pereira, et al.
Publicado: (2019) -
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)